A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Eugenia Girda, Weichung Shih, Marisa Palmeri, Tracie Saunders, Robert M. Berman, Vlad Coric, Suzie Chen, Andrew Zloza, Joshua Vieth, Janice M. Mehnert, Jyoti Malhotra
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors'. Together they form a unique fingerprint.